Drug Profile
Research programme: neurodegenerative disorder therapeutics - Cypralis/Johnson & Johnson Innovative Medicine
Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cypralis Limited; Janssen Pharmaceuticals
- Developer Cypralis Limited; Johnson & Johnson Innovative Medicine; Selcia
- Class Small molecules
- Mechanism of Action Cyclophilin D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in United Kingdom
- 28 Jan 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)